Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece
| Autor: | Theodore Ignatiades, Georgia Ifandi, Emmanuel Diamantopoulos, Maria Spinthouri, Fanis Katostaras, Lycurgus Liaropoulos |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Diclofenac Cost-Benefit Analysis Sensitivity and Specificity Pharmacoeconomics Ambulatory care Internal medicine Osteoarthritis medicine Ambulatory Care Humans Cumulative incidence Hospital Costs Adverse effect health care economics and organizations Randomized Controlled Trials as Topic Pharmacology Sulfonamides Greece business.industry Health Policy Anti-Inflammatory Agents Non-Steroidal Public Health Environmental and Occupational Health Clinical trial stomatognathic diseases Meloxicam Physical therapy business Nimesulide medicine.drug |
| Zdroj: | PharmacoEconomics. 14(5) |
| ISSN: | 1170-7690 |
| Popis: | Objective: To evaluate, from a social security system perspective, the economic consequences of treating rheumatic diseases with nimesulide or diclofenac. Design: Cost-minimisation analysis was used to estimate the incremental direct medical cost and the cost of gastrointestinal adverse events for 15 days’ treatment with nimesulide compared with diclofenac. Cumulative incidence of adverse events was calculated through meta-analysis of the results of double—blind randomised clinical trials. The therapeutic pathway for ambulatory care resource use was determined by a panel of experts, and direct hospital costs were estimated from a sample of 43 patients. Main outcome measures and results: The 15-day treatment cost with nimesulide was 35.9% lower compared with diclofenac due to the lower incidence of adverse events. Our analysis showed that nimesulide generated a cost saving of $US20.98 per patient depending on the dosage of diclofenac used. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink